Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Technology Scientific & Technical Instruments
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Sona Nanotech Inc > Still confused but feeling much better now....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1137)
•••
Comment by Moemoney42on Apr 27, 2021 10:55am
51 Views
Post# 33074090

RE:RE:RE:RE:RE:RE:Still confused but feeling much better now....

RE:RE:RE:RE:RE:RE:Still confused but feeling much better now....KEY WORD.. "PRELIMINARY STUDY" tells me this is another lab test.. not a field test... numbers are bound to change with real "field tests"... 
Kaiser wrote:

Heres a quote and this is not from just the company website lol  you genuinely believe a company would post fake results on their website and open themselves up for lawsuits lol.  Oh wait nvm Sona did that! 


Therma Bright successfully completed a preliminary study of the AcuVid COVID-19 Rapid Antigen Saliva Test to detect the Brazilian P.1 and P.2 variants and the UK B1.1.7 variant. The results showed 100% sensitivity when tested on previously sequenced variant samples.

 

Dude51 wrote: Please provid like to tests of 100%. Please do not provide link to comany website. We all know how that works. Competitors and losers file law suites all the time. Greedy investors drove the price up and then some realized they were had and are trying to recoup there losses. Your probably one of them. lol

 

 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities